EichorEICHOR
Study identifier: NCT07543679 Synced from ClinicalTrials.gov · August 04, 2026
● Recruiting

Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis

Condition: D013493  ·  Sponsor: Centre Hospitalier Universitaire de Saint Etienne

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Systemic sclerosis (SSc) is an autoimmune disease characterized by skin fibrosis, which clinically manifests as thickening, hardening, and loss of elasticity of the skin. Patients are typically classified as having diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc) depending on the extent of skin fibrosis. The standard assessment of cutaneous sclerosis is based on the modified Rodnan skin score (mRSS), which consists of clinical palpation of 17 areas of the body, scored from 0 (normal) to 3 (severe sclerosis) for each area, with a total of 51 points. However, the mRSS has several limitations, including high inter- and intra-observer variability, particularly depending on the clinician's experience, subjectivity of palpation with difficulties in quantifying subtle changes in firmness or elasticity, and limited sensitivity to small changes or in areas that are not severely affected. The assessment of skin fibrosis therefore faces a lack of objective, quantitative tools that are easy to use in routine clinical practice. Certain alternatives have been evaluated (durometer, ultrasound, elastography, etc.), but none has yet been fully adopted or validated for measuring firmness, elasticity, and adhesion at different depths of the skin with good accuracy and reproducibility. ADHELASKIN° technology (by Tactinnov, LTDS / École Centrale de Lyon) enables objective, highly sensitive measurement of rigidity, firmness and elasticity using an indentation method with a ruby bal…

This description comes directly from the study's public registry record.

Talk to the study team

Lucile GRANGE, MD  ·  (0)4 77 82 83 42  ·  Lucile.GRANGE@chu-st-etienne.fr

Clara PFENNINGER, PhD  ·  (0)477120287  ·  clara.pfenninger@chu-st-etienne.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de Saint-EtienneSaint-Priest-en-Jarez, Pays de la Loire Region, FranceRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →